PMID- 11144521
OWN - NLM
STAT- MEDLINE
DCOM- 20010222
LR  - 20151119
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 19
IP  - 3
DP  - 2000 Sep
TI  - Induction chemotherapy for locoregional lung cancer using paclitaxel combination. 
      A preliminary report.
PG  - 291-3
AB  - Induction chemotherapy has been reported to be effective in treatment of locally 
      advanced, borderline resectable, (Stage III), non small cell lung carcinoma 
      (NSCLC). A logical extension of the indication for the induction chemotherapy may 
      be to treat earlier stage resectable lung cancers (stages I and II) because the 
      cure rate of the resectable lung cancers still remains poor and is below 60% 
      except for stage IA. Thirty eight patients with a diagnosis of loco-regional 
      NSCLC were treated with paclitaxel combination chemotherapy. Following two 
      courses of induction chemotherapy, patients underwent surgical therapy whenever 
      possible. There were ten patients with stage I disease, four patients with stage 
      II, 13 with stage IIIA, nine had stage IIIB, and two with stage IV. An overall 
      response rate of 74% was observed. The response rate for 14 resectable patients 
      (stage I and II) was 86%. The chemotherapy regimen was well tolerated and apart 
      from one instance of anaphylaxis, no serious side effects were observed.
FAU - Takita, H
AU  - Takita H
AD  - Thoracic Surgical Dept., Roswell Park Cancer Institute and State University of 
      New York at Buffalo, USA.
FAU - Pitoniak, R F
AU  - Pitoniak RF
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - UM20QQM95Y (Ifosfamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Ifosfamide/administration & dosage/adverse effects
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/prevention & control
MH  - Paclitaxel/administration & dosage/adverse effects
MH  - Treatment Outcome
EDAT- 2001/01/06 11:00
MHDA- 2001/03/03 10:01
CRDT- 2001/01/06 11:00
PHST- 2001/01/06 11:00 [pubmed]
PHST- 2001/03/03 10:01 [medline]
PHST- 2001/01/06 11:00 [entrez]
PST - ppublish
SO  - J Exp Clin Cancer Res. 2000 Sep;19(3):291-3.